Citigroup Inc Curis Inc Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.51 - $0.78 $153,006 - $234,010	-300,013 Reduced 14.04%	1,837,424 $1.1 Million
Q4 2022 Feb 09, 2023	BUY	$0.47 - $17.22 $1 Million - $36.8 Million	2,136,297 Added 187394.47%	2,137,437 $1.18 Million
Q3 2022 Nov 10, 2022	SELL	$0.74 - $15.01 $852 - $17,291	-1,152 Reduced 50.26%	1,140 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.71 - $2.43 $3,612 - $12,363	-5,088 Reduced 68.94%	2,292 $2,000
Q1 2022 May 12, 2022	SELL	$2.31 - $5.13 $1.06 Million - $2.36 Million	-460,325 Reduced 98.42%	7,380 $18,000
Q4 2021 Feb 10, 2022	BUY	$4.45 - $8.09 $1.05 Million - $1.9 Million	235,390 Added 101.32%	467,705 $2.23 Million
Q3 2021 Nov 10, 2021	BUY	$6.94 - $8.85 $1.61 Million - $2.06 Million	232,315 New	232,315 $1.82 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.